The 36-month beta value for MYGN is also noteworthy at 1.94. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 2 rating it as “overweight,” 9 rating it as “hold,” and 3 rating it as “sell.”
The public float for MYGN is 86.78M, and at present, short sellers hold a 4.42% of that float. The average trading volume of MYGN on July 25, 2024 was 835.74K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
MYGN) stock’s latest price update
Myriad Genetics, Inc. (NASDAQ: MYGN) has experienced a rise in its stock price by 0.41 compared to its previous closing price of 28.02. However, the company has seen a gain of 5.73% in its stock price over the last five trading days. zacks.com reported 2024-07-18 that Investors with an interest in Medical – Biomedical and Genetics stocks have likely encountered both Incyte (INCY) and Myriad Genetics (MYGN). But which of these two companies is the best option for those looking for undervalued stocks?
MYGN’s Market Performance
Myriad Genetics, Inc. (MYGN) has seen a 5.73% rise in stock performance for the week, with a 14.09% gain in the past month and a 51.02% surge in the past quarter. The volatility ratio for the week is 4.61%, and the volatility levels for the past 30 days are at 3.64% for MYGN. The simple moving average for the past 20 days is 8.75% for MYGN’s stock, with a 35.09% simple moving average for the past 200 days.
Analysts’ Opinion of MYGN
Many brokerage firms have already submitted their reports for MYGN stocks, with Scotiabank repeating the rating for MYGN by listing it as a “Sector Outperform.” The predicted price for MYGN in the upcoming period, according to Scotiabank is $29 based on the research report published on June 27, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see MYGN reach a price target of $20. The rating they have provided for MYGN stocks is “Underperform” according to the report published on June 03rd, 2024.
Leerink Partners gave a rating of “Outperform” to MYGN, setting the target price at $35 in the report published on May 08th of the current year.
MYGN Trading at 14.83% from the 50-Day Moving Average
After a stumble in the market that brought MYGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -2.65% of loss for the given period.
Volatility was left at 3.64%, however, over the last 30 days, the volatility rate increased by 4.61%, as shares surge +13.04% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +11.63% upper at present.
During the last 5 trading sessions, MYGN rose by +4.58%, which changed the moving average for the period of 200-days by +82.49% in comparison to the 20-day moving average, which settled at $26.03. In addition, Myriad Genetics, Inc. saw 47.00% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MYGN starting from SPIEGELMAN DANIEL K, who sale 3,788 shares at the price of $22.05 back on Jun 04 ’24. After this action, SPIEGELMAN DANIEL K now owns 32,917 shares of Myriad Genetics, Inc., valued at $83,525 using the latest closing price.
SPIEGELMAN DANIEL K, the Director of Myriad Genetics, Inc., sale 3,788 shares at $22.04 during a trade that took place back on Jun 03 ’24, which means that SPIEGELMAN DANIEL K is holding 36,705 shares at $83,488 based on the most recent closing price.
Stock Fundamentals for MYGN
Current profitability levels for the company are sitting at:
- -0.41 for the present operating margin
- 0.69 for the gross margin
The net margin for Myriad Genetics, Inc. stands at -0.42. The total capital return value is set at -0.24. Equity return is now at value -29.41, with -20.58 for asset returns.
Based on Myriad Genetics, Inc. (MYGN), the company’s capital structure generated 0.23 points at debt to capital in total, while cash flow to debt ratio is standing at -0.28. The debt to equity ratio resting at 0.29. The interest coverage ratio of the stock is -113.0.
Currently, EBITDA for the company is -67.8 million with net debt to EBITDA at -0.69. When we switch over and look at the enterprise to sales, we see a ratio of 4.82. The receivables turnover for the company is 4.83for trailing twelve months and the total asset turnover is 0.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.99.
Conclusion
In summary, Myriad Genetics, Inc. (MYGN) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
